Ras homolog gene family member A (RhoA) has been identified as a critical regulator of tumor aggressive behavior. In this study, we assessed the role of RhoA in the mechanisms underlying growth, migration, and invasion of squamous cell carcinoma of tongue (TSCC). Stable RhoA knockdown of TSCC cell lines SCC-4 and CAL27 were achieved using Lentiviral transfection. The effects of RhoA depletion on cell migration, invasion, and cell proliferation were determined. The possible underlying mechanism of RhoA depletion on TSCC cell line was also evaluated by determining the expression of Galectin-3 (Gal-3), b-catenin, and matrix metalloproteinase-9 (MMP-9) in vivo. Meanwhile, the underlying mechanism of TSCC growth was studied by analysis of cyclin D1/2, p21 CIP1/WAF1 , and p27
Introduction
Approximately 260,000 new cases of head and neck squamous cell carcinoma (HNSCC) are diagnosed each year, which makes it the seventh most common cancer worldwide [1, 2] . Squamous cell carcinoma of tongue (TSCC) is one of the most common malignant neoplasms in HNSCC, accounting for 30% of all oral cancers [3] with ,50% of 5-year survival rate, despite the advances in the therapeutic management of TSCC over the last decades [4] . The poor prognosis is mainly due to local invasion and distance metastasis, which are regulated by multiple genes [5, 6] . Therefore, elucidation of these genes and the pattern of their expression may provide useful novel target(s) in developing therapeutic drugs in treatment of such devastating disease.
Rho family GTPases regulate cytoskeletal dynamics, thereby affecting multiple cellular functions including cell motility and polarity [7, 8] . Rho proteins alternate between an active guanosine-5 0 -triphosphate (GTP)-bound state and an inactive guanosine diphosphate (GDP)-bound state. In the active form, GTPases stimulate effectors that coordinate various cellular processes such as migration, proliferation [9] , gene expression [10] , and cytoskeletal organization. The Rho subfamily includes the isoforms RhoA, RhoB, and RhoC, which are 84% identical in sequence [11] . Despite the high homology of these three different Rho isoforms, their physiological roles are distinct [12] . For example, RhoA and RhoC localize to the plasma membrane or interact with RhoGDI in the cytoplasm, whereas RhoB localizes to endosomal membranes and regulates endosomal trafficking of membrane receptors [11, 13] . The role of RhoB in these processes appears to be more divergent, whereas RhoA and RhoC have been shown to have a positive role in proliferation and malignant transformation [14, 15] . It has been demonstrated that RhoA with high expression positively regulates cell invasion and metastasis in ovarian [16] , breast [17] , lung [18] , and colorectal cancer [19] . RhoA was reported to be correlated with oral squamous cell carcinoma [20] . Meanwhile, inhibition of RhoA, as a downstream effector for some oncogenes, is known to be associated with invasion [21] and growth [22] of some HNSCC. Therefore, specifically inhibiting the functions of RhoA has been predicted to be of therapeutic benefit. However, the molecular mechanisms underlying RhoA-mediated inhibition on cancer cell invasion and growth remain unclear.
In this study, to understand the role of RhoA in TSCC, the effect of targeted suppression of RhoA on cell growth, migration, and invasion were examined in tongue cancer cell lines and tumors. We found that knockdown of RhoA is sufficient to inhibit several aspects of malignancy in TSCC.
Materials and Methods
Cell culture and siRNA infections SCC-4 and CAL27 cell lines ( provided by Stomatolgy Research Center of Shandong University, Shandong, China) were cultured in Dulbecco's modified Eagle's medium (DMEM) medium (Invitrogen, Carlsbad, USA), supplemented with 10% fetal bovine serum (FBS) (Hyclone, Logan, USA), 100 U/ml penicillin and 100 U/ml streptomycin (GIBCO, Gaithersburg, USA). All cells were maintained in a humidified atmosphere of 5% CO 2 at 378C. When these cells reached 30% confluence, they were transfected with siRNA-RhoA-Lentivirus ( purchased from Shanghai GeneChem, Shanghai, China) at a multiplicity of infection of 50 for 24 h in DMEM containing 10% FBS and 5 mg/ml polybrene. The sequences of the RhoA and controls were listed as follows: siRNA-RhoA-1 sequence, 5
0 -AUGGAAA GCAGGUAGAGUU-3 0 ; siRNA-RhoA-2 sequence, 5 0 -GA ACUAUGUGGCAGAUAUC-3 0 ; and control-siRNA sequence, 5
0 -CCAGAAGAGCAAU-CUGUAC-3 0 . For the tumor model, 3 weeks after tumor cell injection, 10 8 transducing units of siRNA-RhoA-Lentivirus or control-RhoALentivirus in 20 ml DMEM containing 10% FBS and 5 mg/ml polybrene were injected in the tumors once a day for 3 days continuously.
Tumor xenograft model and tumor size measurement Six weeks old BALB/c nu/nu mice with a body weight of 20-25 g were purchased from SLAC (Shanghai, China). The SCC-4 and CAL27 cells were injected (2 Â 10 5 in 0.1 ml medium) submucosally into marginal part of tongue at the cross-point of forward 1/3 and backward 2/3 in 48 mice. These mice were divided evenly into four groups for each of SCC-4 and CAL27. There were six mice in siRNA-RhoA-1, siRNA-RhoA-2, control siRNA, and untreated group, respectively. The male and female mice were in half and divided randomly. After formation, each tumor was measured once every 2 days by using a caliper and the following formula was used to calculate tumor volume (V):
2 , where A and B represent the larger and smaller tumor diameters, respectively [23] . The size was measured three times for each mouse and the final average volume was determined in each group. Graphs were plotted to illustrate tumor growth. Mice were maintained in specific pathogen-free, temperature-controlled isolation conditions, fed with sterilized food and autoclaved water. Animal breeding, care, and experimental procedures were approved by ethical and humane committee of Qingdao University and carried out strictly in accordance to the related ethical regulations.
Western blot analysis
The cells were harvested after treatment of siRNA-RhoA or control-siRNA for 96 h. RNA isolation and real-time reverse transcriptase-polymerase chain reaction Total RNA was extracted from the cells of each group at 48 h after infection using Trizol and reversely transcripted into cDNA using the PrimeScript RT-PCR kit (TaKaRa Bio Inc., Shiga, Japan) according to the manufacturer's instructions. Primers and fluorescent probes were synthesized by Shanghai Sangon Biological Engineering Technology & Services Co., Ltd (Shanghai, China). The levels of RhoA and control b-actin mRNA transcripts were determined by the real-time reverse transcriptase-polymerase chain reaction in ABI7500 real-time thermal cycler (Applied Biosystems, Foster City, USA). The polymerase chain reactions in duplicate were subjected to an initial denaturation at 958C for 10 s, followed by 40 cycles of denaturation at 958C for 5 s, annealing and extension at 608C for 45 s. The value of threshold cycle (CT) for each reaction was recorded. The following primer sets were used:
0 (fluorescent probe). All experiments were performed in triplicates.
Cell proliferation assay Cell proliferation was measured by a methyl thiazolyl tetrazolium (MTT) assay. Cancer cells (2.0 Â 10 3 cells per well) were seeded in 96-well microtiter plates in a total volume of 100 ml/well. Infection was performed when cells were 30%-40% confluent. Then, 10 ml/well of CCK-8 was added for 4 h. The absorbance of each well was determined at 450 nm using a microtiter plate reader (Molecular Devices, Sunnyvale, USA). The results are expressed as mean + standard deviation (SD) from triplicate cultures.
Scratch assay
The cell migration was determined using a wound-healing motility assay [24] . The infected cell lines were seeded on a 24-well plate with their respective culture media and grown until confluence. After scratching with a pipette tip, the monolayer of cells was washed three times with phosphatebuffered saline (PBS) to remove the detached cells. The remaining adherent cells were cultured in DMEM containing 1% FBS for 24 h and then the media was replaced with DMEM containing 10% FBS. The filling of the spaces were evaluated at 48 h after siRNA infection using bright-field microscopy. All experiments were performed in triplicate.
Cell invasion assay
Cell invasion assay was performed using a BD BioCoat Matrigel Invasion Chamber (Becton-Dickinson, Franklin Lakes, USA). Cells were harvested at 48 h after infection. Cells were re-suspended in serum-free DMEM and then added to the upper chamber at a density of 2 Â 10 5 cells per well. Cell invasion into the Matrigel was determined, following 24 h culture at 378C. The polyethylene terephthalate (PET) membrane containing invading cells was fixed with methanol, Wright's stained, and quantified by light microscopy, after removing non-invading cells on the upper side of the membrane in the upper chamber with cotton swabs.
Immunohistochemical assay
Paraffin-embedded sections were deparaffinized in xylene, and rehydrated in serially diluted ethanol (100%, 95%, 75%, 50%, and 0%). After washing with distilled water for 5 min, sections were incubated with 3% methanol for 10 min to quench endogenous peroxidase. For antigen retrieval specimens, the sections were boiled in citrate buffer under full vapor pressure for 2 min, and washed in distilled water and PBS/0.1% Tween-20. After incubation with 150 ml of protein block (Dako, Glostrup, Denmark) for 5 min, samples were incubated overnight at 48C with 200 ml of polyclonal anti-Galectin-3 antibody (1 : 80, Thermo Fisher, Fremont, USA) and anti-b-catenin antibody (1 : 100, Thermo Fisher), respectively. The following day, sections were washed with PBS/0.1% Tween-20 and incubated with 100 ml of goat antirabbit antibody conjugated with HRP (Dako) or alkaline phosphatase (AP; Dako) for 30 min. After washing with PBS/0.1% Tween-20, proteins in the tissues were visualized by incubation in diaminobenzidine for HRP or permanent red for AP. Finally, tissue sections were counterstained with Mayer's hematoxylin, mounted and analyzed with a light microscope. Omission of primary antibody was used as the negative control. The immunohistochemical analysis for different proteins was repeated at least three times. The expression of Galectin-3 (Gal-3) and b-catenin in the cytoplasm/ nucleus was evaluated, and the percentage of tumor cells that expressed targeted protein was determined. The ratio between the number of tumor cells that express Gal-3/ b-catenin and the whole number of tumor cells in the tissue section was calculated. The expression was categorized as follows: absent (0% of cells), low (,25% of cells), moderate (between 25% and 75% of cells), or high (.75% of Effects of RhoA knockdown on tongue cancer cells cells). For analytical purposes, the variable was dichotomized as low expression (,25% of cells) and high expression (25%-100%) [25] .
Statistical analysis
Statistical analyses were carried out using SPSS software (Ver. 16.0, SPSS Inc., Chicago, IL, USA). The results were presented as mean + SD, and statistical significance was determined using analysis of variance analysis and SNK-q test. A value of P , 0.05 was considered statistically significant.
Results
RhoA protein levels are elevated in primary TSCC tumors and metastasized lymph nodes In the xenograft TSCC model, visible tumors were formed 2 weeks after SCC-4 or CAL27 cell injection into the tongue. To test whether RhoA is up-regulated in TSCC, we analyzed the expression of RhoA protein from the extracts of primary TSCC tumors, lymph node metastases, or surrounding normal tissue by western blot. The protein level of RhoA was significantly increased in both types of TSCC tumors compared with that in the normal tissues (Fig. 1A) . Four weeks after tumor cell injection, metastasized submandibular lymph nodes could be detected by palpation and be confirmed by pathological examination. Metastasized lymph nodes also showed significantly higher RhoA protein levels compared with non-metastasized lymph nodes (Fig. 1B) .
Silencing RhoA inhibits proliferation of TSCC cells
We silenced RhoA in SCC-4 and CAL27 cells using virus particles harboring the respective siRNAs. A significant inhibition of RhoA at both mRNA and protein levels was detected at 48 h following gene silencing of RhoA, whereas there was no significant difference observed between untreated and control-siRNA-infected cells in any of the cell lines ( Fig. 2A,B) . siRNA treatment led to 73% and 60% knockdown of RhoA in SCC-4 and CAL27 cell lines, respectively.
To assess the effect of RhoA knockdown on proliferation activity of TSCC cells, SCC-4 and CAL27 cells were seeded onto 96-well microplates and cell growth was determined by a continuous 3-day MTT assay. At 48 and 72 h after treatment, cells infected with RhoA-siRNA showed significantly lower activity than the control groups (Fig. 3A) . This result suggests that knockdown of RhoA in TSCC cells by siRNA inhibits cell proliferation in vitro.
Silencing RhoA reduces migration and invasion of TSCC cells Scratch assay demonstrated that total numbers of migrating cells were reduced in RhoA-siRNAs infected cells compared with that in the other two control groups (Fig. 3B) . The time required for space closure of RhoA-silenced tongue cancer cells was significantly longer than that of control cells (data not shown). RhoA-siRNA treatment affected cell invasion similarly to migration of tongue carcinoma cell lines (P SCC-4 , 0.05; P CAL27 , 0.05). Total numbers of migrating cells on PET membrane were sharply decreased in the RhoA-siRNA-treated groups, compared with the control groups (Fig. 3C) . These results indicate that RhoA modulates tongue cancer cell migration and invasion, at least in vitro.
For the control-siRNA-treated mice, the metastasized lymph nodes were generally detected 4 weeks after tumor cell injection, which is 1 week after RNAi. However, for the RhoA-siRNA mice, metastasized lymph nodes were found 1-2 weeks later (data not shown). The metastasized lymph nodes were excised and confirmed by pathological examination (Fig. 4A ) at 2 weeks after siRNA treatment. This result suggests that the metastasis progress of TSCC was inhibited to a certain degree by RhoA suppression.
Silencing RhoA results in the suppression of Gal-3, b-catenin, and matrix metalloproteinase-9 expression To investigate the molecular mechanisms of invasion and migration of SCC-4 and CAL27 cells in the xenograft models, we analyzed the expression levels of Gal-3, b-catenin, and matrix metalloproteinase-9 (MMP-9) using Effects of RhoA knockdown on tongue cancer cells western blotting on the seventh day after siRNA treatment. The levels of Gal-3, b-catenin, and MMP-9 in TSCC tumors were significantly decreased in the RhoA-siRNA group compared with those in controls (Fig. 4B) . Meanwhile, to further confirm the alteration of Gal-3 and b-catenin expression in SCC-4 and CAL27, the immunohistochemical assay was conducted. Expression of Gal-3 and b-catenin in the nucleus and cytoplasm was detected in both SCC-4 and CAL27 tumors. A higher expression of Gal-3 and b-catenin in the cytoplasm was found than that in the nucleus, and the expression levels of Gal-3 and b-catenin was decreased significantly after RhoA silencing (data not shown, Fig. 4D ).
Silencing RhoA induces cell cycle arrest and the growth of TSCC tumors To further investigate the effect of RhoA silencing on TSCC tumors, we examined the effects on cell cycle regulators involved in the G1/S transition, namely cyclin D1/2, p21 CIP1/WAF1
, and p27
Kip1
, in SCC-4 and CAL27 tumors on the seventh day after siRNA treatment. RhoA suppression caused a significant decrease in cyclin D1/2, and a significant increase in p21 CIP1/WAF1 and p27 Kip1 in primary TSCC tumors (Fig. 4C) . This result suggests that RhoA deficiency induces cell cycle arrest in TSCC cells. In accordance with this finding, RhoA-siRNA treatment significantly reduced the growth of primary TSCC tumors in mice (Fig. 4E) .
Discussion
TSCC is significantly more aggressive than other forms of HNSCC, with a propensity for rapid local invasion, spread, and a high recurrence rate [26, 27] . Despite improvements in surgery, radiotherapy, and chemotherapy, the prognosis for TSCC patients has not significantly improved for the past three decades. Improvement in patient survival requires better understanding of tumor invasion and metastasis so that Effects of RhoA knockdown on tongue cancer cells aggressive tumors can be inhibited early in the disease process, and so that targeted therapeutic interventions can be developed.
Rho GTPases have been implicated in the progression of cancer in various organs, including breast [17] , lung [18] , and colon [19] . Small GTP-binding proteins of the Ras superfamily are involved in such diverse cellular functions as cell motility, proliferation, apoptosis, cell cycle progression, and invasion and metastasis of malignant tumor cells [28, 29] . RhoA, for example, act as a molecular switch to control signal transduction pathways by cycling between a GDP-bound, inactive form and a GTP-bound, active form. RhoA is over-expressed in premalignant dysplastic and HNSCC cell lines in comparison with normal keratinocytes and correlated with a poor outcome [30] , which suggests that it is a promising biomarker of malignancy and/or aggressiveness in HNSCC [30] . In support of this finding, we showed here that RhoA was present in TSCC xenograft tumors at a much higher level than normal squamous epithelium, and was also highly expressed in metastasized lymph nodes. Our findings suggest that endogenous RhoA expression correlates with tumor invasion, metastasis, and growth of TSCC.
The formation and growth of metastasis is the principal cause of death for most cancer patients, particularly those with HNSCC [31, 32] . RhoA regulates the activities of multiple transcription factors, most of which are implicated in the cancer progression by modulating cancer cell adhesion, contraction, movement, release of cellular adhesion, degradation of extracellular matrix, and invasion into blood or lymph vessels [33, 34] . Our study focused on whether RNAi-mediated suppression of RhoA could be used to arrest migration and invasion of TSCC and be demonstrated as a strategy for future therapy. Our data showed that the migration and invasion of TSCC cells were inhibited after RhoA knockdown. This inhibition was further proved in our research by a significant reduction of MMP-9 expression after RhoA silencing. MMP-9 is the strongest signal for invasion and metastasis among the MMPs [35] and is correlated with poor outcome in HNSCC [36] . RhoA-induced increase of MMP-9 expression may be an important contributor to the highly invasive and metastatic behavior of TSCC cells. However, to clarify how RhoA regulates MMP-9, further investigations of the detailed mechanisms of RhoA-induced MMP-9 production and activities are necessary.
We have previously demonstrated the involvement and significant positive role of Wnt/b-catenin in TSCC [37] . In this study, we found that the suppression of RhoA decreased the expression of Gal-3 and b-catenin.
Expression analyses of HNSCC and HNSCC-derived cell lines have shown that most tumors and cell lines Effects of RhoA knockdown on tongue cancer cells over-express Wnt signaling pathway components [38, 39] , and that nuclear b-catenin localizes at the invasion front in carcinomas [39] . Gal-3 is a b-galactoside-binding animal lectin that contains carbohydrate-recognition domains and displays multiple related functions [40] . High expression of Gal-3 in the cytoplasm transmitted from nuclei positively is correlated with cell invasion [41] and poor clinical prognosis [42] . Gal-3 expression is proved to be lower in the nucleus than in the cytoplasm in tongue cancer [43] , which is in accordance with our study. b-Catenin is a key multifunctional adaptor protein harboring functions that are related to the subcellular location [44] . In the cytoplasm and within the membrane, b-catenin binds to intracellular E-cadherin and plays a role in cell adhesion and maintenance of normal cellular architecture. Down-regulation of b-catenin leads to the inhibition of cell invasion and metastasis in HNSCC [45, 46] , cervical carcinoma [47] , and prostate cancer [48] . Wnt/b-catenin pathway was proved to be involved in the invasion of tongue cancer in our research. Therefore, inhibition of b-catenin is a potential mechanism for the reduced growth and delayed metastasis of TSCC tumors in our model.
Control of cell cycle progression in cancer cells is considered to be an effective strategy for the inhibition of tumor growth [49, 50] . Our MTT results showed a suppression of TSCC cell growth by RhoA silencing, which is in line with the results in esophageal squamous cell carcinoma [51] . To further investigate the mechanism of regulating cell proliferation by RhoA, we analyzed the levels of cyclin D1/2, p21 CIP1/WAF1
Kip1 in vivo. Cyclin D1/2 can accelerate the G1/S phase transition and promotes cell growth and division, and its over-expression is considered to be an important factor in the promotion of tumor occurrence and development [52, 53] . Over-expression of p27
Kip1 has been revealed to inhibit Cyclin-dependent kinase (CDK) activation and entry into the S phase of the cell cycle [38] , and loss of its function may subsequently contribute to tumorigenesis [54, 55] . Reduced expression of p27
Kip1 has been found in Effects of RhoA knockdown on tongue cancer cells gastric, breast, and non-small-cell lung cancers [56, 57] , and is correlated with poor clinical prognosis in head and neck cancers [58, 59] . p21 CIP1/WAF1 leads to either cell cycle arrest at the G1 checkpoint or apoptosis [60] and prevents mammalian cell proliferation as well as inhibits all cyclin-CDK complexes [61] . We found a decrease in the level of cyclin D1/2 after RhoA silencing, which suggests that the RhoA-siRNAinduced G1 phase arrest may be mediated through the up-regulation of the CDK inhibitory proteins p21 CIP1/WAF1 and p27 Kip1 . G1 phase arrest of cell cycle progression provides an opportunity for cells to either undergo repair mechanisms or follow the apoptotic pathway. This is in line with the finding that the growth of RhoA-silenced tumors was inhibited in our study.
RhoA is well known to be essential for many fundamental cellular processes [16, 17, 23] and is associated with the malignant behavior of various tumors [26, 45] . The present investigation suggests that RhoA is related to the malignant behavior of TSCC through its up-regulation of cell growth by accelerating cell cycle progression and its up-regulation of cell motility and invasiveness by activating the Wnt/ b-catenin signaling pathway. Thus, RhoA appears to be a potential novel target for the treatment of TSCC.
